Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) Director William K. Heiden bought 100,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, November 10th. The shares were acquired at an average cost of $0.25 per share, for a total transaction of $25,000.00. Following the completion of the purchase, the director now directly owns 209,000 shares of the company’s stock, valued at approximately $52,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Atara Biotherapeutics Trading Up 9.3 %
NASDAQ ATRA opened at $0.38 on Thursday. Atara Biotherapeutics, Inc. has a 12 month low of $0.20 and a 12 month high of $5.64. The stock has a market cap of $38.75 million, a P/E ratio of -0.14 and a beta of 0.98. The stock’s fifty day moving average price is $1.36 and its 200-day moving average price is $1.73.
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03). Atara Biotherapeutics had a negative net margin of 6,390.31% and a negative return on equity of 783.31%. The business had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $2.20 million. As a group, analysts forecast that Atara Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Evercore ISI cut Atara Biotherapeutics from an “outperform” rating to an “in-line” rating in a research note on Thursday, November 9th. StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 2nd. HC Wainwright cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. Finally, Mizuho cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.00.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
- Five stocks we like better than Atara Biotherapeutics
- What Are Dividend Achievers? An Introduction
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- How to Invest in Canada for Beginners
- 5 reasons TJX Companies will hit new highs in 2024
- 3 Healthcare Dividend Stocks to Buy
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.